Watson Pharmaceuticals searches for two new presidents

Share this article:
Watson Pharmaceuticals announced it has initiated a search for two newly created president positions for each of the Corona, Calif.-based company's business units – brands and generics.
As a result of this new management structure, Joseph Papa, Watson's chief operating officer and president, will leave the company Nov. 19.
"Following our decision in June to focus on generics and specialty brand products, including urology and nephrology, we have continued to implement strategies to increase our focus in these specialty areas," said Allen Chao, Watson's chief executive. "We believe having a president in each business unit will enhance our ability to maximize the growth of each business."
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...